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ABSTRACT 
 
Background: Glioblastoma multiforme (GBM) is an incurable and fatal brain cancer with 
short median survival. Due to the infiltrative growth into the surrounding brain parenchyma, 
radical surgery is not possible and their infiltrative growth patterns provide one of the biggest 
challenges to effective treatment. However, quite few experimental therapies targeting tumor 
invasion have been performed and none have prolonged survival in patients. An important 
mechanism underlying infiltrative growth involves the migration of tumor cells along 
myelinated nerve fibres (white matter tracts).  Cuprizone is a neurotoxic demyelinating agent 
which is used to study autoimmune diseases of CNS in immunocompetent mice. Since 
myelinated nerve fibres provide a substrate for glioblastoma cell migration, we hypothesized 
that cuprizone could inhibit the infiltrative growth of glioblastoma xenografts. Since highly 
infiltrative brain tumor models are based on xenografting human GBM biopsies, this requires 
an immunodeficient host such as nude rats or SCID mice. However, whether the cuprizone 
model for demyelination can be established in immunodeficient strains is not known. Thus the 
work presented in this thesis describes the establishment of cuprizone model for 
demyelination in NOD/SCID mice. Subsequently, we used the model to investigate the effect 
of cuprizone on the growth of GBM xenografts.    
 
Method: Four NOD/SCID mice above 18 kg of weight, 4-8 weeks of age, both male and 
female were fed cuprizone to analyse if it caused demyelination.  All mice were offered a 
daily portion (5 g per mice) of standard mice diet mixed with 0, 2 % cuprizone and were 
provided with water ad libitum. MRI was taken two, four, six and eight weeks after adding 
cuprizone to the diet. One brain was harvested at each time points for MRI scanning and fixed 
in formalin for histopathological analysis and immunohistochemistry. This analysis confirmed 
progressive demyelination during the diet, indicating that the cuprizone model could also be 
established in NOD/SCID mice.  We then administered cuprizone to five more NOD/SCID 
mice that had been xenografted with GBM spheroids one week prior to starting the diet. 
These mice were compared to mice harboring GBM xenografts that received a regular diet. 
We then performed a second experiment where five additional mice were put on a Cuprizone 
diet two weeks prior to implanting them with GBM spheroids. Again these were compared 
with control mice that were also implanted with GBM spheroids but received a normal diet 
without Cuprizone. Weight and survival data were collected and the brains were harvested 
and fixed for the histopathological analysis and immunohistochemistry (IHC).     
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Results: Our results demonstrate that NOD/SCID mice exhibit cuprizone-induced 
demyelination of the corpus callosum, progressive hydrocephalus and depletion of 
oligodendrocyte precursor cells. Mice that were xenografted with GBM spheroids one week 
prior to staring the cuprizone diet did not show prolonged survival compared to the control 
group. However, mice that received cuprizone before GBM implantation had a significantly 
longer survival than the control mice. Moreover, immunohistochemistry showed less 
infiltration of proliferating tumor cells in the tumor periphery, as well as recruitment of 
microglia to both the tumor centre and periphery.  
 
 
Conclusion: The present study has proved that cuprizone-induced demyelination in NOD/ 
SCID mice provides an adequate animal model to investigate how demyelination impacts on 
the growth of GBM xenografts. Moreover, IHC against tumor proliferating cells after 
inducing demyelination show that the myelin sheaths are important substrates for glioma cell 
migration. Prolonged survival in the cuprizone group also suggests that interactions between 
glioma cells and the myelin sheaths are targets for anti-invasive glioma therapy. However, the 
therapeutic potential of cuprizone is highly questionable, due to its toxic effects. In contrast, 
novel compounds that block the attachment of glioma cells to the myelin sheath without 
causing structural damage, may have a big potential as anti-invasive compounds for gliomas.  
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1. INTRODUCTION 
1.1 General aspects of cancer  
 
Cancer is a disease in which cells with genetic aberrations exhibit uncontrolled growth. 
Although the cell of origin is not known, it is known that cancers develop clonally. They arise 
from one cell which passes its mutations on to the daughter cells (2). Full malignant 
transformation requires several genetic changes which are often acquired step-wise over 
several years (3-5). The affected cells can be classified into oncogenes and tumor-suppressor 
genes (6). Oncogenes are mutations in genes that normally promote cell growth (proto-
oncogenes). Thus oncogenes are gain-of-function mutations where increased amounts of 
proteins or altered activity contribute to tumor progression. Oncogenes are dominant as 
mutation in one allele is sufficient to promote tumor growth. On the other hand, tumor-
suppressor genes suppress cell growth and induce apoptosis. In cancers, tumor-suppressor 
genes are often inactivated leading to increased cell proliferation and disruption of apoptotic 
pathways. Thus, these genetic changes are referred to as loss-of-function mutations. Tumor-
suppressor genes are recessive since mutations in both alleles are required.   
Most cancer types share some common defining traits. These traits are indentified as 
phenotypic hallmarks of cancers (7-9) :  
- Growth signal autonomy:  
Cancer cells do not rely on external growth factors but are self-sustained with growth-
promoting signals 
- Avoidance of growth inhibitory signals: 
Cancer cells exhibit resistance to growth inhibitory signals 
- Evasion of apoptosis: 
 Cancer cells evade apoptotic signals 
- Unlimited replicative potential: 
Cancer cells exhibit the ability for indefinite growth and cell division 
- Sustained angiogenesis: 
Cancer cells induce growth of new blood vessels to secure a sufficient supply of oxygen 
and nutrients  
- Invasion and metastasis: Cancer cells have the ability to invade surrounding tissue 
and spread to distant body parts.  
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Over the past decade, the perception of tumor biology has evolved revealing the necessity for 
establishing further cancer hallmarks which allow the cancer cells to grow and invade healthy 
tissue. The cancer cell’s capabilities to manipulate their stroma to create a favourable 
microenvironment are additional changes needed for mutated cells to grow and spread. The 
cancerous cells may need to reprogram the cellular energy metabolism, or to actively dodge 
from the attack and the eradication by immune cells in order to sustain survival and growth. 
Cancer cells also exhibit genomic instability and obtain increasingly more genetic aberrations 
during the disease course (8).  This new biological perception of cancer indicates that cancer 
should not be viewed as a cancer cell–isolated pathogenesis, but rather as a disease involving 
a complex interaction with other cells in the microenvironment. Furthermore, this up-to-dated 
understanding of tumor biology indicates the need for a modern therapeutic approach in order 
to control the disease.   
 
In recent years, the cancer stem cell hypothesis has been postulated.  According to this 
concept, tumors contain small subpopulations of cells that have the ability to self-renew as 
well as to differentiate into other tumor cell types with a more limited replicative potential. 
Thus the cancer stem cells drive tumor progression and create the cellular heterogeneity seen 
in many tumor types. Reportedly, cancer stem cells have been indentified in several tumor 
types, such as leukemias (10-12) and brain tumors (13-18). However conflicting data have 
been published by several groups (19-21) and this concept is a controversial issue.  
1.2 Glioblastoma multiforme (GBM) 
 
Glioblastoma multiforme represent the biggest group of primary bran tumors. They are 
classified by their similarity to the glial cell types, and graded by their degree of malignancy. 
Glioblastoma multiforme is the most common and aggressive malignant primary brain tumor. 
They can not be radically removed due to their infiltrative growth and radio- and 
chemotherapy prolong survival only modestly. Thus, GBMs have a dismal prognosis with 
almost 100% mortality rates and a short median survival in the range of ca 14 months (22).  
The incidence of GBM is about 2-3/100 000/year, and they are slightly more common 
amongst men. The only established risk factor is ionising radiation. Histopathologically, they 
are characterised by mitotic figures, cellular atypia, necrosis, and microvascular proliferation 
(angiogenesis). 
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Fig: 1.2: A coronal section of a GBM.  The figure shows a primary lesion in on the left basal 
ganglia followed by a secondary lesion in the right hemisphere due to the migration of cancer cells 
across the corpus callosum.  The figure is adapted from P. Kleihues (23) 
 
 
Moreover, glioblastoma can develop in patients not previously diagnosed with a brain tumor 
(GBM) or from a more low-grade glioma (secondary GBM). 
1.2.1 Primary and secondary glioblastoma multiforme 
 
GBMs are genotypically heterogeneous and there is no single mutation that is common to all 
GBMs. However, many mutations are seen in varying proportions of GBMs. It has also been 
proved that primary (low grade) and secondary (high grade) GBMs develop through different 
genetic pathways. They have different rates of anaplastic progression and are observed in 
patients of different ages (24) . 
Secondary GBM harbour TP53 mutations and usually affect younger patients. The 
progression from low-grade glioma through an anaplastic astrocytoma and finally a GBM 
may take 10-15 years. In contrast, primary GBMs develop in older patients and typically 
involve loss of heterozigozity of 10q (70% of cases), EGFR amplification (36%), p16(INK4a) 
deletion (31%), and PTEN mutations (25%) (25). The high grade GBMs are more common 
than secondary GBMS (> 90 %) (25, 26). 
 
 
Disseminated GBM from 
the left basal ganglia  
 Right basal ganglia 
Left basal 
ganglia 
GBM 
Corpus callosum 
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Figure1. 1: A sketch showing genetic alterations associated with the development of GBMs.  The WHO 
grading system is added. The World Health Organization (WHO) classifies the primary brain tumors into four 
grades, based on various histological features, and to their resemblance of cells of origin within the CNS (27, 
28). WHO Grade I, II astrocytomas (respectively Pilocytic and diffuse acystroma) are characterised by a  very 
low level of proliferation, while grade III (anaplastic astrocytoma)  exhibits diffuse anaplasia, a relatively 
high degree of mitotic activity and proliferation as compared to grade I and II.  Grade IV (glioblastoma 
multiform) exhibits a high diffuse infiltration and necrotic areas in the centre of the tumor masse.  The 
frequencies of the genetic alterations are shown as percentages. Figure modified from Ohgaki and Kleihues  
(25). 
 
During the past decades, the grading of gliomas has relied on the WHO classification system, 
based on various histological features and the resemblance of tumor cells with the main CNS 
types. However, DNA sequencing and gene expression profiling have identified GBM 
subgroups that correlate with different survival outcome. The Cancer Genome Atlas (TCGA) 
data has been used to identity subgroups in human gliomas (29). In addition, results from the 
recent cohort study using the genomic sequential method in gliomas (29, 30), grouped GBMs 
into proneural, classical and mesenchymal probable GBM subtypes. Mutations within these 
groups are currently used as markers for prognosis. For example mutated IDH1 and mutated 
TP53 have been observed to be associated with improved survival in subgroups of young 
patients (30). However, gene expression is also influenced by epigenetic alterations such as 
 
Malignant progression of astrocytic gliomas 
Low-grade Astrocytoma 
TP53 mutations (59 %) 
 
WHO Grade II 
Anaplastic Astrocytoma 
TP53 mutations (53 %) 
 
WHO Grade III 
 
Secondary glioblastoma 
EGFR amplification (8 %), p16 (INK4a) 
deletion (19 %), TP 53 (65 %) 
 
WHO Grade IV 
Primary glioblastoma  
EGFR amplification (36 %), 
p16 (INK4a) deletion (31 %), 
 
WHO Grade IV 
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metylations which are not detected by sequencing (31). Thus, methylation and gene 
expression analysis can provide additional information about the biology of gliomas.  
1.2.2 Glioma cell invasion and biological mechanisms 
 
The GBM is the fastest growing type of astrocytoma and quickly spreads and invades nearby 
normal brain tissue. They rarely spread to other parts of the body (2, 32), but invade locally 
by realising factors that modulate the CNS microenvironment which, in return, accommodates 
their motility (33-35). The GBM invasion employs interactions between malignant cells, glial 
cells, neural cells and endothelial cells involving  proteolytic enzymes,  cell adhesion 
molecules and specific cell surface receptors (36).  Notably, the tumor-stroma interplay 
mediates the spread of the glioblastoma cells into other regions of normal brain parenchyma 
(37) by migrating along the white matter fiber tracts such as the corpus callosum (38, 39). In 
addition, tumor cells may be passively distributed with the cerebrospinal fluid to distant sites 
within the CNS such as the spinal medulla.  
1.2.3 Glioblastoma multiforme (GBM) therapy 
 
As previously mentioned, GBMs are incurable due to their infiltrative growth. The existing 
treatments can prolong survival by months and decrease the symptoms (brain oedema, 
headaches, seizures, different types of neurological deficits, etc.). Several centres advocate a  
standard treatments of GBMs that include maximal resection of > 95% of the tumour, 
followed by adjuvant concurrent chemotherapy and  radiotherapy, and maintenance therapy 
with temozolomide depending on predictive and prognostic factors (22, 40, 41). This 
approach is still under survey, and it is suggested that the results might improve the median 
and 5-year survival with 3-5 % for the patients.  Several novel molecular target therapies for 
GBMs are also under investigation, including HER1/EGFR tyrosine kinase inhibitors 
(Gefitinib, Erlotinib), angiogenesis inhibitors (Bevacizumab), mTOR inhibitors (Everolimus 
Rapamycin, Deforolimus and Temsirolimus), and farnesyl transferase inhibitors (42). However, 
none of these have yet prolonged survival for patients in randomised clinical trials.   
 
 
 
 
  
 
13 
Figure 1.3: The pathogenesis of multiple sclerosis: 
demyelinated neuronal axon leading to interruption in nerve 
impulse.  
1.3 Multiple sclerosis 
 
Multiple sclerosis (MS) is a 
chronic inflammatory 
neurodegenerative disease  
affecting  the oligodendrocytes 
with their  myelin sheaths 
around the axons of neurons in  
the central nervous system 
(CNS) (43). The myelin sheath 
plays an important 
physiological roll, serving as 
insulation around the nerve 
fibres in the human central nervous system, and is necessary to increase the transmission 
speed of the electrical signals. Thus, demyelination inhibits propagation of action potentials 
along the axons, disrupting the communication between neurons in the CNS.  
 
The abnormal communication between the brain and the rest of the body leads to different 
neurological symptoms of multiple sclerosis (44). Thus, multiple sclerosis is characterised by 
plaques in affected regions, inflammation, axonal injury and progressive physiological 
disability. It mostly develops in people between 20-40 years and it is 2-3 times more common 
in women than in men (45). In Norway there are about 5000 to 8000 who are affected by the 
disease (46). The aetiology of the disease in human is not known, but potential causes 
includes genetic, infections, physical and emotional stress, climate and diet (47). 
1.3.1 The pathology and the pathological subgroups of human 
multiple sclerosis 
 
The immunological processes causing multiple sclerosis is  not fully understood (48), but they 
target the oligodendrocytes and the myelin (49).  In the early stage, the inflammatory process 
involves microglia, macrophages ,  B-cells, their antibody products and T-cells in the central 
nervous system (50). It is often followed by disruption of the blood-brain barrier (BBB) (48, 
51), allowing proliferating T- and B-cells to migrate across the BBB into the CNS. These 
attacks lead to thinning or complete loss of myelin (52). The restoration of the myelin 
(remyelination) can occur during the early progression of the disease (acute inflammatory 
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lesions), followed by a functional recovery and clinical remittance. However, the 
oligodendrocytes can not completely rebuild the myelin sheet, thus repeated attacks ultimately 
leaves a scar and axonal injury/loss (53). The progression of multiple sclerosis disease differs 
from person to person. Based on the clinical course, MS is classified into three main clinical 
groups (46, 54-56): 
- Relapsing-remitting MS (RRMS); representing the initial course of the disease and 
characterized by discrete attacks evolving over days to weeks (rarely over hours). The 
symptoms appear in episodes of exacerbations (relapses) and it may take months or 
years between relapses.  
- The secondary progressive MS (SPMS) is the course after RRMS; the presenting 
symptoms increase gradually to become chronic.  
- The third course refers to primary progressive MS (PPMS) where patients have 
gradually increasing symptoms from the onset without remissions.  The disease is 
characterized by steady deterioration leading to continuous increase in neurological 
deficits without clear relapses or periods of remission.    
- The progressive/relapsing MS (PRMS) overlaps PPMS and SPMS.  
1.3.2 Toxic demyelination models allowing to study MS pathology in 
animal experiments 
 
The neurodegenerative demyelination in MS disease have been mimicked in the animal model 
producing similar histopathology changes (57). Three models for demyelinating diseases are 
widely used, namely EAE (58), Theiler’s virus induced encephalitis, and toxic demyelinating 
model (48, 59).  In EAE, immunization with myelin antigens induces inflammatory 
demyelination in the CNS. In Theiler’s virus induced encephalitis, the mice are infected with 
the neurotropic picornavirus, leading to the demyelinating disease.  In the toxic demyelinating 
model, chemical agents such as lysolecithin, ethidium bromide, or cuprizone are used to 
induce demyelination.  The cuprizone is a commonly used model  to study corpus callosum 
demyelination (60). 
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Table1.1: Description of four different pathological patterns in early MS-lesion.  
Pathological features of early lesions in different animal models used for investigating MS in 
humans (61-63) 
 
Patterns Pathological characteristics Mediating  factors 
in human MS 
Experimental animal 
model allowing to 
study  MS pathology 
I Demyelinated plaque, T-
lymphocyte and macrophage 
dominated inflammation with 
relative preservation of 
oligodendrocytes 
 
Macrophage or/and 
their toxic  products 
 
 
 
Autoimmune 
encephalomyelitis 
(AEA)  
 
II 
 
The patterns resembles pattern I, 
and has additionally Ig reactivity 
Specific 
demyelinating 
antibodies and 
compliments 
Autoimmune 
encephalomyelitis 
(AEA) 
 
III 
 
Active demyelination, 
complement activation , 
preferential loss of myelin 
associated glycoprotein (MAG),  
lesions are infiltrated with T-
lymphocytes, macrophages and 
activated microglia 
 
Degenerative changes 
in oligondrocytes 
followed by apoptosis 
 ( myelin sheath are 
not targeted) 
 
Therapeutic model 
using  
toxin – induced 
demyelination 
 
IV 
 
Roughly demarcated plaques of 
demyelination, olygodendrocytes 
death exposed by DNA 
fragmentation. 
 
Primary degeneration  
of oligodendrocytes 
followed by myelin 
destruction (myelin 
sheath are not 
targeted) 
 
Therapeutic model 
using  
toxin – induced 
demyelination 
 
1.3.2.1 Cuprizone, a copper chelator agent 
 
In mice, cuprizone can be used as a model for toxic demyelination (64). The demyelinating 
effect of cuprizone is mediated by its copper chelating chemical reaction targeting directly 
oligodendrocytes, leading to progressive loss of oligodendrocytes (65). However, the 
underlying mechanisms of cuprizone-induced toxic effects on oligodendrocytes in CNS are not 
fully understood. It has been suggested that the cuprizone binds copper in the oligodendrocyte 
cellular membrane and that subsequent depletion of cupper ions which are vital for enzymatic 
activity in the mitochondria leads to myelin damage. 
 
It has been shown that the cuprizone neurotoxic effect is strain dependent  (66), and the  
C57BL/6 mice is now frequently used for demyelination/remyelination studies  as it 
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recapitulates the neuro-pathological patterns similar to those observed in the human multiple 
sclerosis disease (48, 57, 62, 63, 66-77). They appear in form of focal lesions in the corpus 
callosum region, followed by recruitment of microglia. The myelin loss occurs as a 
consequence of primary loss of oligodendrocytes, and remyelination, mediated by 
oligodendrocyte progenitor cells (OPCs) can occur upon withdrawal of cuprizone treatment 
(78). However, the lack of myelination and chronic persistent MS lesions following depletion of 
oligodendrocyte progenitor cells can also be studied with prolonged cuprizone treatment more 
than 8 weeks. The toxic effect of cuprizone also cause radiological and structural changes in the 
CNS of C57BL/6 mice, such as dilated ventricles (hydrocephalus) in the brain parenchyma 
(65). 
1.3.3 Multiple sclerosis therapy 
 
Multiple sclerosis disease is an incurable disease. However, a number of treatments for acute 
attacks, or for reduction of the biological activity (disease-modifying agents) are obtainable.   
The drugs like corticosteroids can be used in acute exacerbation of the disease to improve 
symptoms and shorten time of disability and the immunomodulatory treatment using interferon 
for example, can be used to slow the destruction of myelin. In addition, different symptomatic 
treatments can improve symptoms such as cognitive loss, depression, paranoid, visual 
disturbances, etc (symptomatic treatments). The medical treatments for MS which are available 
do not cure or prevent the disease, but they rather reduce the disease activity, limit disability 
and delay disease progression (79). Findings suggest that an  individual therapeutic approach is 
efficient, reducing the clinical relapses and associated inflammation in the CNS,  and delaying 
the disease deterioration and subsequent disabilities (79). Thus the current therapies, combined 
with high standards of care, may offer the patients a normal life span.  
1.4 NOD/SCID mice models  
The animal models for cancer research are generally based on any of three approaches: 
chemical induction, transgenic animal models or xeno-transplantation models (80), the latter 
often involving immunodeficient mice to study tumor (81). Moreover, the xeno-transplantation 
model have been used in clinical research, testing potential pharmaceutical agent and the 
success has rendered this technique an important tool in pharmaceutical commerce (82). Severe 
combined immunodeficiency (SCID) mice carry a homozygous mutation causing a lack of 
functional B-and T-cells. In addition, the mutation in these mice is transferred onto non-obese 
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diabetic (NOD) background to avoid the development of partial immunity (leakiness). Due this 
deficiency, the mice allow for engraftment of human tissue (80), such as cancer cell lines or 
tumor biopsies (83). Previously, experimental representative brain tumor models derived from 
human GBM biopsies have been established in NOD/SCID mice. However, NOD/SCID mice 
have not to our knowledge been validated as a host model to study demyelination.  
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2. AIM OF THE STUDY 
Glioblastoma multiforme is an incurable disease due to its infiltrative growth. The myelin 
sheath around the nerve fibers provides a substrate for migration of glioma cells. Multiple 
sclerosis is a demyelinating disease affecting the oligodendrocytes and their sheaths. 
Relatively few reports of MS patients diagnosed with GBM have been reported. Thus we 
wanted to investigate whether demyelination could inhibit tumor growth and invasion.   
 
The aim of the work was: 
 
1- To establish an animal model for demyelination in NOD/SCID mice using cuprizone. 
 
2- Administer cuprizone to NOD/SCID mice grafted with GBM biopsy spheroids to 
investigate how the demyelination impacts on tumor growth.   
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3. MATERIAL  
3.1 Mice 
Table 3.1: Description of the mice used in this experimental study   
 SPECIES  Mus musculus, inbreeding laboratory mice 
STRAIN ( international nomenclature):  NOD/SCID 
SOURCE Local breeding at the Vivarium 
GENETIC STATUS (if not  obvious from 
stock/strain designation) 
Homozygous for   Prkdcscid   genotype and the 
dsred reporter transgene 
AGE and/or WEIGHT at start of 
experiment: 
3-8 weeks; 15-35 g 
SEX Male and female 
MICROBIOLOGICAL STATUS The mice are tested in accordance with the 
FELASA requirements(84). Every 3 months 10 
animals from the sentinel animal population should 
be subjected to a full microbiological and 
pathological examination.  
QUARANTINE or ACCLIMATIZATION  
Since this is local breeding, the mice are in the same facility throughout their life span. They are 
transferred to the cages used for the experiments 1 week prior to the start of the experiments. 
HEALTH MANAGEMENT OF ANIMALS UNDER  
 
Measures to protect microbiological status  
Closed system IVC cages 
 
Housing equipment (types, material, dimensions, possibly cage type) 
IVC cages (73 X 65 X 13) cm 
 
Number of animals per cage or housing unit: 4-6 mice 
 
Bedding: The bedding is delivered from Scanbur BK and is routinely tested to ensure that its 
content does not affect the experiments. In addition the environment is enriched with different 
other materials including paper and plastic elements.  
 
Environment temperature (0c -+ range), relative humidity:  Temperatures is maintained in the 
range 18-22 °C. 
Lightning: 12 light/12 dark cycles is used.  Entrance to the mouse room and lightning during the 
dark cycle is avoided.  
Air changes per hour: 18 
Feeding: The food pellets, called “RM1”  rodent maintenance diet containing wheat, barley, de-
hulled extracted toasted soya, soya protein concentrate, macro minerals, soya oil, whey powder, 
amino acids, vitamins and micro minerals. Water: Tap water ad libitum. 
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  3.2 In vivo experiments 
 
Table 3.2.1 Chemicals 
  Chemicals Catalogue number supplier 
 
Isofluran 
 
J109020 
Schering Plough Animal 
Health, Ballerup, Denmark 
 
Marcain 2.5 mg/ml 
 
- 
AstraZeneca, Södertälje, 
Sweden 
 
Cuprizone 
 
C9012-25G 
 
Sigma-Aldrich, co, Austria 
 
Omniscan  0,5 mmol/ml 
 
107789930 
GE Healthcare,  Nycomed 
Amersham, Oslo, Norway 
 
 
Table 3.2.2 Equipment 
 Equipment 
 
Supplier 
 
Stereotactic frame 
 
David Kopf Instruments, Tujunga, CA, USA 
 
Temperature controller 
 
World Precision Instrument (WPI), Inc. 
 
Germinator 500 
 
Cell point scientific, Gaithersburg, MD, 
USA 
 
Sutures 
 
 
Ethicon, Norderstedt, Germany 
 
Surgical sponges 
 
Neurotechnics limited, Oxfordshire, UK 
 
7T MR scanner 
Bruker Biospin MRI GmbH, Ettlingen, 
Germany 
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Table 3.2.3 Cell biopsy 
Spheroids Cell type Supplier 
 
P3 
 
Human Glioblastoma 
 
 
Haukeland University 
Hospital, Bergen, Norway 
 
 3.3 Cell culture 
 
Table 3.3.1 Chemicals 
Chemicals Catalogue number Supplier 
Dulbecco’s modified eagle’s 
medium (DMEM) 
 
D5671 
Sigma-Aldrich Inc, St. Louis 
USA 
 
Dulbecco’s phosphate 
buffered saline 10X (PBS) 
 
BE17515F 
 
Sigma-Aldrich Inc, St. Louis 
USA 
 
L_Glutamine (Gln) 
 
BE17605E 
 
Cambrex, New Jersey, USA 
Non-essential amino acids 
(NEAA) 
 
BE13114E 
 
Cambrex, New Jersey, USA 
Penicillin/Streptomycin 
(PenStrep) 
 
DE17603E 
Bio Whittaker Inc, 
Walkersville, USA 
Plasmocin ant-mpt InvivoGen, Calfornia, USA 
 
Trypsin 
 
17161 
Lonza Walkersville Inc, 
Walkersville, USA 
 
 3.4 Apparatus and software 
 
Equipment Supplier 
 
Lamin Airflow cabinet 
 
Het-Holten A/S, Denmark Medionor ASA 
 
Light-microscope Olympus IX2-SLP 
 
Olympus, Tokyo, Japan 
 
Light-microscope Nikon Eclipse E600 
 
Nikon, Tokyo, Japan 
MRI scanner Siemens Magneton vision, Erlangen, 
Germany 
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3.5 Immunohistochemistry 
 
Table 3.5.1: chemicals 
 Chemicals Catalogue number Supplier 
 
Citrate buffer 
 
W302600 
 
Sigma –Aldrich, Belgium 
 
 
TBS Tween buffer (TBST) 
10X 
 
S3306 
 
 
DakoCytomation, Glostrup, 
Denmark 
 
 
Peroxidase block buffer 
 
 
547500 
 
DakoCytomation, Glostrup, 
Denmark 
 
 
DAKO protein block 
 
 
S3022 
 
DakoCytomation, Glostrup, 
Denmark 
 
 
DAB chromogen and DAB 
solution/buffer 
 
Acu-250 
 
DakoCytomation, Glostrup, 
Denmark 
 
Ethanol 
 
 
600068 
 
Arcus Kjemi, Vestby, 
Norway 
 
 
Harri Hematoxylin solution 
 
 
RBA-4213-00A 
 
Kjemi-Teknikk as, Norway 
 
Heating bath 
 
 
HBR4 
 
IKA Werke, GmbH & Co, 
Staufen, Germany 
 
Xylene 
 
 
33817 
 
Sigma-Aldrich Inc, St. 
Louis, USA 
 
EDTA 
 
 
ED2SS 
 
Sigma-Aldrich, Inc, St. 
Louis, USA 
 
ABC-complex 
 
 
PK - 7100 
 
Vector Laboratories, 
Burlingame 
 
Entellan Neu  
 
1079610100 
 
Merck KGaA, Darmstadt, 
Germany 
 
Luxol fast blue 
 
MBSN-1328-51-4 
 
ChemExper Inc., Belgium. 
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Table 3.5.2: Antibodies 
 
Antibodies 
 
Dilution 
 
Catalogue number 
 
Supplier 
 
Primary antibodies 
 
 
Ki-67 mouse- 
monoclonal 
 
1:100 
 
M7240 00045312 
 
DAKO Cytomation, 
Glostrup, Denmark 
 
NG2 rabbit- 
polyclonal 
 
1:100 
 
AB81104 
 
ABCAM, Cambridge, 
UK 
 
CD68 mouse-
monoclonal 
 
1:100 
 
M081401 
 
DAKO Cytomation 
Glostrup, Denmark 
 
Secondary antibodies 
 
 
Goat anti-mouse 
 
1:100 
 
1070-11L 
 
Southern Biotech, 
Birmingham, 
Alabama, USA  
 
Goat anti-rabbit 
 
1:100 
 
BA_1000 
 
Vector Laboratories, 
Burlingame 
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4.  METHODS 
4.1 Mice strain 
 
 NOD/SCID mice, male and female, with a minimum of weight of 18 g were used. All 
laboratory procedures involving mice were in accordance both with the guidelines 
implemented by the Ethical committee / National Animal Research Authority (NARA). The 
animals were sacrificed by gas stunning (asphyxiation by CO2), followed by cervical 
dislocation.    
4.2 Study design and cuprizone treatment 
4.2.1 Cuprizone test in SCID mice 
 
Four NOD/SCID mice, 4-8 weeks of age, both male and female were fed 0, 2% cuprizone to 
analyse if cuprizone induces demyelination in central nervous system, a similar pathological 
pattern observed in established animal models for human multiple sclerosis.  MRI was taken 
on the second, forth, sixth and eighth week after cuprizone administration and the brain from 
one mouse was harvested and fixed in formalin at each scanning and was cryosectioned for 
immunstaining and histopathological analysis. All mice were offered a daily portion (5 g per 
mice) of standard mice diet mixed with 0, 2 % cuprizone and were provided water ad libitum.  
 4.2.2 Experimental therapy targeting invasion of GBM  
  
19 mice, 4-8 weeks of age, both male and females were grouped randomly into 2 groups: one 
intervention group (n=10) and one control group (n=9). These groups were further divided 
into 2 experiments, in which cuprizone treatment was started at different time points (see 
below):  
 
 
 
 
 
 
 
 
  
 
25 
Experiment  I Experiment II 
Intervention approach mimicking the  therapy 
after diagnose,  where cuprizone was 
administered one week after gliomas 
implantation  
Intervention approach where the therapy is 
targeting gliomas invasion, and cuprizone 
was administered 3 weeks before glioma 
implantation 
Cuprizone groupe Control group Cuprizone groupe Control group 
 
5 mice 
 
4 mice 
 
5 mice 
 
5 mice 
 
9 mice 
 
 
10 mice 
 
 All untreated groups in each category were fed normal diet and provided water ad libitum 
while the treated groups were offered a daily portion (5 g per mice) of normal diet mixed with 
0, 2 % cuprizone. The MRI for all mice in each experimental group was taken on six and 
eight weeks after cuprizone administration. Apart from the diet, the same protocols for 
implantation, pre- and post-operative procedures were applied in all animals.  
 
4.3 Biopsy tissue collection 
The GBM biopsy was harvested with the informed consent of patient at the operation theatre 
at the Department of Neurosurgery, Haukeland University Hospital. The use of human 
biopsies in cancer research is approved by the Regional Ethical Committee. The specimen 
was collected using a standard procedure (85) as follows: the biopsy was  taken  from tumor 
areas appearing macroscopically viable, corresponding to regions with contrast enhancement 
on preoperative magnetic resonance imaging (MRI) scans and immediately transferred under 
aseptically conditions to test tubes containing a complete growth medium, which consisted of 
DMEM, supplemented with 10% fetal bovine serum (FBS), 2% L-glutamine, and 4× the 
prescribed concentration of nonessential amino acids, penicillin, and streptomycin. 
 
4.4 Tissue culture and spheroid cells preparation 
From the GBM biopsy material, tumor spheroids were prepared as previously described (85). 
In short, samples were minced into 0.5-mm fragments, placed into 80-cm
2
 tissue culture 
flasks (Nunc, Roskilde, Denmark), and base coated with 10 mL of 0.75% agar (Difco, Detroit, 
MI) in culture medium (DMEM). The spheroids were maintained in a standard tissue culture 
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 Figure 4.1: Animal immobilized in a stereotactic frame 
during surgery. 
 
incubator with 5% CO2 in air and 100% relative humidity at 37°C and the medium was 
changed once weekly. After 1 to 2 weeks in culture, spheroids with diameters between 300 
and 400 µm were selected for i.c. implantation. The spheroids used in this experiment were 
established from GBM xenografts using the same procedure as described above for making 
GBM spheroids. 
4.5 Anesthesia 
Inhalation of Isofluran 5% (Schering Plough Animal Health, Ballerup, Denmark) combined 
with N2O was used as general anesthesia, and 0, 2 ml 0.1 % marcain was injected 
subcutaneously in the scalp as a local anesthesia about halfway between the ears. Before 
implantation, the mice were anesthetized in an induction chamber supplied with 5 % 
isofluran. The isofluran dosage was adjusted to 2-3 % during surgery.  The respiration and the 
body temperature of animal under anesthesia were monitored and regulated using a 
temperature controller with a heating plate and a rectal probe, keeping the rectal body 
temperature of the mouse at approximately 37 
0
C.    
4.6 Injection of glioma spheroids 
 
Five tumor spheroids (300-400 
micrometer in diameter) were 
selected under light microscope 
(Nikon, Tokyo, Japan) using a 
50 µl syringe. The spheroids 
used in the last experiment 
were somewhat bigger than the 
spheroids in the first 
experiment, due to limited 
availability. When the animal 
was unconscious it was 
immobilized in a stereotactic  
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 Figure 4.2 –The point of drilling through which injection of tumor cells was done is 
marked with a brown dot. Adapted from Reference (1).
 
 
frame and the head locked in position with ear and nose bars as shown in figure 4.1.   
 
During the course of spheroids injection, the mice lied on a heating pad which was connected 
to a thermometer that was put into the mice’ s rectum, and we  made sure that the mice had a 
constant body temperature of 37 degrees Celsius. An incision was made in the skin to access 
the skull, starting behind the eye going caudally 2 cm. The skin was held away from the 
exposed skull with one bulldog clip on each side of the incision. The point where bragma and 
sutura sagittalis meet was then located (figure 4.2). A whole in the bone was drilled at the 
coordinates: x= 1.5 mm right of the sagittal suture (midline), y= 0.5 mm behind the bragma 
suture. A cell suspension was injected over 1-2 minutes with a mikroliter syringe z= 1.5 mm 
under the cortical surface. The skin was carefully closed with three sutures. The mice was 
then released from the nose and ear bars and moved to an infant incubator where it was kept 
until to wake up.  
 
 
 
 
 
 
 
 
Retracted skin 
Location of drilling 
Bregma 
Suttura  
sagittalis 
Ear bars 
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Figure 4.3: MRI scanner. The picture is used with permission from 
Molecular Imaging Center (MIC), University of Bergen 
 
4.7 In-house small animal MRI scanner  
 
The magnetic resonance imaging (MRI) was used to visualize the brain tumor and to study the 
structural changes in the 
mice brains.  MR images 
were acquired using a 7T 
horizontal bore small-
animal MR scanner 
(Pharmascan, Bruker 
Biospin) with a linear 
transmitter/receiver 
mouse-head volume coil. 
Animal were anesthetized 
using 1-2 % isofluran 
mixed with equal parts 
N2 and O2 (50/50) 
supplied via a cone mask. 
All animals were placed in a prone position in the animal cradle containing a heating pad at 
37 
0
C. Respiration was monitored throughout the experiment using dedicated animal 
monitoring equipment (SA Instruments).  
 
The MRI protocols was as follows: MR sequences used include T2-weighted RARE sequence 
with TR/TE of 4200/35.2 ms, FLAIR sequence with TR/TE of 3200/9.2 ms and inversion 
time TI of 1500 ms, and T1-weighted RARE sequence before and after subcutaneous 
injection of contrast agent Gadodiamide (1.0 ml of    0.5 mmol/ml Omniscan mixed with 
NaCl (1:1); Nycomed Amersham, Oslo, Norway, Omniscan; GE Healthcare) with TR/TE 
1000/9.0 ms.  T1 and T2 weighted sequences had FOV of 2.0 x 2.0 cm and a matrix size of 
256 x 256, while FLAIR had a FOV of 2.0 x 2.2 cm and a matrix of 256 x 256. 12 slices, each 
1 mm thick were collected in all sequences. The combination of T1-, T2-weighted and 
FLAIR, sequences gave complementary information which allowed us to visualize the tumor 
structure and localize the tumor vicinity in the mouse brain.  
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4.8 Histological examination and immunohistochemistry (IHC) 
 
In this study, we used luxol fast blue staining (LFB, ChemExper Inc., Belgium) to assess 
demyelination. Luxol blue stain was used to mark myelin fibers. Myelin fibers will appear 
blue following stain with LFB and can be observed under light microscope (57, 86).  
Additionally, we performed immunohistochemistry (IHC). Different primary antibodies were 
used. Mouse monoclonal anti-Ki67 antibody (DAKO Cytomation, Glostrup Denmark) was 
used as cellular marker for human cell proliferation to determine the fraction of proliferating 
cells in the tumor bulk and to detect tumor cells.  Rabbit polyclonal anti-NG2 antibody 
(ABCAM, Cambridge, UK) was used to identify oligodendrocyte precursor cells.  Mouse 
monoclonal anti-CD68 antibody (DAKO Cytomation, Glostrup Denmark) was used to detect 
microglia and other macrophages.  
4.8.1 Luxol fast blue (LFB) staining  
 
The paraffin sections were deparaffinised by using toluol and hydrate to 95% ethyl alcohol 
and were then left in luxol fast blue solution in 56 
0
C ovens overnight. The slides were rinsed 
with 2-3 times in 95% ethyl alcohol.  The sections were then rinsed in distilled water, before 
being dipped in 0, 5 % lithium carbonate for 15 – 30 seconds. Thereafter, the slides were 
rinsed in 2-3 times of 70 % alcohol. The rinsed slides were thereafter rinsed twice in distilled 
water. The sections were dipped four times in 70 % cresyl fiolet to stain the nuclei,  followed 
by one dip in xylen 96 %   (5sec), 1 dip in xylen 100 % (1 minute), and 1 dip 100 % (1 
minute). Then the slides were mounted with xylene based mounting medium (Merck, 
Germany9 and were left to dry.  
4.8.2. NG2; Ki-67; and CD68 staining 
 
Paraffin sections of xenografted mice brain were stained using the manufacturer’s protocol for 
immunostaining of paraffin sections Avidin-Biotin-Complex (ABC, Vector Laboratory, and 
Burlingame). Sections were deparaffinised by washing in xylol (2x5 minutes), 100 % ethanol 
(2x3 minutes), 96 % ethanol (2x3 minutes) and ddH2O for 2 minutes. The sections were put in 
citrate buffer pH 6 and antigen retrieval was performed by heating at the boiling point for 20 
minutes in a water bath. Sections were cooled down to room temperature under running tap 
water, dried, and washed with PBS-Tween (DAKO Cytomation, Glostrup Denmark). 
Peroxidase block buffer was applied for 5 minutes before sections were washed 3 times with 
PBS-Tween and incubated with protein block for 30 minutes. The protein block was 
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discarded and 50-100 µl primary antibody added (Ki-67 mouse monoclonal or NG2 rabbit 
polyclonal or CD68 anti-mouse) and incubated first for one hour at room temperature, and 
then 4
o
 C overnight in a humid chamber. All antibodies were diluted 1:100 in TBST/ 5% 
serum.  
The sections were then washed three times in PBS-Tween. Goat anti-mouse antibody (Ki-67 
and CD68) and Goat anti-rabbit secondary antibody (NG2) were added and sections were 
incubated at room temperature for ~45 minutes. Again, the sections were washed three times 
in PBS-Tween. Sections were then developed by adding 80 µl of DAB-solution (DAKO 
Cytomation, Glostrup Denmark) to each slide. The process was monitored under a light-
microscope and stopped by adding dH2O and washing with PBS-Tween when positive 
staining was visible, after approximately 3 minutes for NG2 and 45 seconds for Ki-67. The 
sections were placed in dH2O until all the slides were developed. Counterstaining was 
performed by placing the slides in Hematoxylin for approximately 15 seconds, followed by 
rinsing under tap water. Finally, the sections were dehydrated trough 96 % ethanol (2x3 
minutes), 100 % ethanol (2x3 minutes) and xylene (2x5 minutes) before they were mounted 
onto coverslides using xylene-based mounting medium. The slides were allowed to dry in a 
fume hood overnight.  
4.9. Quantification of cells 
 
Ki-67 index was determined by taking pictures of the tumor sections under a Nikon light 
microscope (Nikon, Tokyo, Japan) at x 40 magnification. A grid was applied over each 
picture using the Nikon software, with a grid size of 100 µm. All nuclei within 4 squares were 
marked and subsequently all Ki-67 positive nuclei were marked using a different colour.  The 
fraction of all nuclei that was also Ki-67 positive was then calculated. Ki-67 index was 
calculated both in areas from the tumor bulk and in areas from the tumor periphery. Two 
tumors from controls and two tumors from Cuprizone treated mice were examined.  
4.10 Statistics 
 
Statistical analysis was performed using the GraphPad Prism 5 software. Weight curves were 
analysed during the repeated measures one-way Anova test. Survival analysis was conducted 
using the Log-rank test in two groups. A student t-test was used to test statistical differences 
between Ki-67 index for mice on standard diet vs. Cuprizone diet. Differences were accepted 
  
 
31 
as statistically significant at p < 0.05. Standard error of the mean are indicated in figures 
through the text. 
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5. RESULTS 
5.1. Cuprizone effects in NOD/SCID mice 
 
 
 
Figure 5.1.1: Weight loss during administration of 0.2 % cuprizone. 4 mice were given a 
daily diet of 5 g/mouse and their weights were recorded from start of the treatment  
(p = 0. 031)  
 
In order to determine whether the cuprizone model for demyelination could be established in 
NOD/SCID mice, we first characterized the effects of cuprizone in NOD/SCID mice without 
tumors. As shown in figure 4.1, mice uniformly showed a significant weight loss. Although, 
the weight reduction varied within the group, there was a significant, approximately a 15 % 
average weight loss for the whole group (P = 0.031) following treatment with 0.2 % 
cuprizone 
 
Moreover, we wanted to investigate if this mice strain exhibited the same radiological 
changes that were previously described in the C57BL/6 strain (48).  Notably, NOD/SCID 
mice also showed increasing dilation of the ventricular system during the first 6 weeks (Fig. 
5.1.2). However, the ventricular system was less dilated after 8 weeks. T1-weighted 
sequences after administering contrast agent did not show any contrast-enhancement (Data 
not shown). 
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Figure 5.1.2: MRI coronary brain scans of NOD/SCID mice on normal diet and cuprizone 
diet at different time points. Upper panels: T2 weighted rare sequence, lower panels:  
FLAIR sequence. Both sequences demonstrate progressive dilation of the ventricular 
system (Hydrocephalus) up to 6 weeks (n=4). 
 
 
In order to directly assess the effect of cuprizone on demyelination, we conducted luxol fast 
blue (LFB) staining of the mice brain sections and subsequently examined them under a light 
microscopy (Fig. 5.1.3). Luxol fast blue staining stains the intact myelin fibers in a strong 
blue colour.  
 
Figure 5.1.3: Luxol fast blue staining with (LFB) of NOD/SCID mice brains on normal 
diet and at different time points, as indicated, on cuprizone diet. Shown are coronary 
sections of Corpus Callosum in the midline (upper panels) and over the lateral ventricle 
which both exhibit progressive loss of myelin (n=2). Scale bar: 200 µm. 
 
Although there were some variations, the overall pattern showed a progressive loss of myelin 
from 2 to 8 weeks. Thus, at the latest time point there was a striking thinning of the Corpus 
  
 
34 
Callosum compared to untreated control. This was apparent both in the thickest part in the 
midline as well as over the lateral ventricles.    
 
     
Figure 5.1.4: Immunohistochemistry (IHC) against NG2 (brown), a marker for 
oligodendrocyte precursors, nuclear counterstaining with Hematoxylin (blue). Whereas 
NG2-positive cells (arrowheads) are present in brains from untreated controls, mice brains 
are depleted of NG2-positive cells after 8 weeks of cuprizone treatment (n=3).  Scale bar: 
100 µm. 
 
The potential for remyelination after cuprizone treatment relies on oligodendrocyte precursors 
reconstituting the pool of oligodendrocytes. Previously, Torkildsen et al. reported that 
oligodendrocyte precursors were depleted following 8 weeks of treatment with Cuprizone. 
Thus we performed IHC against NG2 of mice brains from animals treated with cuprizone for 
8 weeks and untreated controls (figure 4.1.3). While numerous NG2-positive cells were 
present in normal brains, there was a striking almost complete loss of NG2-positive cells after 
8 weeks treatment with cuprizone.   
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5.2. Cuprizone used as the therapeutic intervention in the glioma 
xenograft model 
 
Since the myelin sheaths around nerve fibers provide an important substrate for glioma cell 
migration, we wanted to investigate whether cuprizone-demyelination impacted on the 
invasive growth of GBM xenografts and overall tumor progression.  
5.2.1 On set of cuprizone treatment after implantation of GBM 
spheroids  
 
In the first experiment, mice were first implanted with GBM spheroids and 0.2 % cuprizone 
was administered 2 weeks after implantation, whereas a control group were given the same 
diet without cuprizone. The mice were weighed once a week and revealed a significant weight 
loss in mice fed on cuprizone compared to control mice, starting from the 3
rd
 week.  
 
 
    
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2.1.1:  Weight loss in tumor bearing mice fed on 0, 2 % cuprizone. (P=0.19, 
cuprizone diet: n=5, normal diet: n=4) 
 
We monitored tumor growth in vivo using MRI, and confirmed tumor engraftment in both 
groups at 6 weeks. Like expected at 8 weeks, all tumors had clearly grown. Moreover, some 
control tumors had longer extensions on T1-sequences and more extensive oedema on T2-
sequences. In contrast, some of the cuprizone treated tumors seemed more circumscribed. 
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Figure 5.2.1.2: MRI brain scans of mice harbouring GBM xenografts on normal diet 
(A) vs. cuprizone diet (B), time points and imaging sequence as indicated. Tumor 
lesions are visible on T1-sequences as white/greyish lesions due to contrast 
enhancement. Note contrast-enhancing tumor extension (arrowhead) in control tumor 
A, upper right panel). Oedema is visualised on T2 sequences as high signal (lighter) 
areas. Tumor associated oedema (arrow) can be seen in control tumours into the 
contralateral hemisphere (A, lower left panel). 
 
 
Also, we collected survival data for the animal which were sacrificed at the onset of 
symptoms.  One animal in the treatment group died after 3 weeks before scanning, but did not 
show any tumor on histological examination. The two groups produced overlapping survival 
curves without significant differences (p = 0.19). 
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Figure 5.2.1.3:  Survival from the time of implantation in mice harbouring GBM 
xenografts in NOD/SCID mice on normal or cuprizone diet (P=0.19) 
 
 
5.2.2: Onset of cuprizone treatment prior to implantation of GBM 
xenografts 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure: 5.2.2.1: Weight curves for mice on normal diet vs. 0.2 %cuprizone diet started 3 
weeks before implantation of GBM spheroids. (P=0.045, cuprizone: n=5, controls: n=5) 
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In the next experiment, mice were fed 0.2 % cuprizone 3 weeks prior to implantation of GBM 
spheroids. The animals were weighed once a week and showed that cuprizone-treated mice 
experienced a significant weight loss compared to the control group after 6 weeks (p= 0.04).  
 
5.2.2.2: Survival from the time of implantation to the onset of symptoms in mice on 
cuprizone vs. standard diet (p= 0.0027) 
 
Animals were sacrificed at the onset of symptoms, 12-48 days after treatment. Notably, all 
animals in the control group succumbed to their tumours 12-38 days after implantation of 
GBM spheroids. In contrast, animal on the cuprizone diet developed symptoms 43-48 days 
after implantation. Thus, animals on the cuprizone diet lived significantly longer than animals 
on a standard diet. 
Since cuprizone treated animals lived longer, we performed IHC for the proliferation marker 
Ki-67 to investigate whether cuprizone inhibited glioma cell proliferation. For comparison, 
we assessed the fraction of Ki-67 positive cells in the tumor bulk from cuprizone treated 
tumors with controls. We found a relatively equal number of Ki-67 positive cells although 
there was slightly more Ki-67 positive cells in the cuprizone treated tumors, and the 
difference was not significant. Since the brain is largely a post-mitotic organ, we also used Ki-
67 staining to identify proliferating tumor cells migrating along corpus callosum in the tumor 
periphery. Interestingly, this area showed a significantly higher infiltration of Ki-67 positive 
tumor cells in the control tumors compared to cuprizone treated tumors (p= 0.009) 
 
 
P = 0. 0027 
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Figure 5.2.2.3: A) Immunostaining against Ki-67 (brown) in brain tumor sections from 
mice on standard vs. cuprizone diet. Nuclear counterstaining: Hematoxylin (Blue). Areas 
from the tumor bulk as well as the periphery were compared between mice on cuprizone vs. 
standard diet.  Scale bar: 100 µm. B) Quantification of Ki-67 index between the two groups 
in areas from the tumor bulk (upper panel) and the periphery (lower panel). Scale bar: 100 
µm 
 
 
Since macrophages, including microglia are recruited both to tumors and areas of 
demyelination, we conducted immunostaining against the CD68-epitope, a marker for 
microglia and other macrophages (Fig. 5.2.2.4). In the tumor bulk (upper panels), there were 
numerous CD68-positive cells in both groups. However, there seemed to be more 
immunopositive cells in the bulk of cuprizone treated tumors (upper right panel). The 
invasion zone also contained CD68-positive cells, although these areas uniformly displayed a 
weaker staining (lower panels). Also in the tumor periphery, cuprizone-treated tumors seemed 
to contain more CD68-positive cells. 
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Figure 5.2.2.4: Immunostaining against CD68 (Brown) in areas from the tumor bulk 
(upper panels) and tumor periphery (lower panels) from cuprizone-treated tumors and 
control tumors. Nuclear counterstaining: Hematoxylin (Blue). Scale bar = 100 µm. 
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6. DISCUSSION 
Cuprizone is a toxin which is used to induce demyelination in mice, thereby providing a 
model for multiple sclerosis. Its effect in rodent experiments is mediated through its copper 
chelating chemical reaction, targeting primarily the oligodendrocytes. Thus, the subsequent 
loss of myelin sheath is due to loss of oligodendrocytes (65) .The model is used  to study 
autoimmune mechanisms underlying demyelination of the white matter tracts, and corpus 
callosum is the structure which is most investigated (60). In the present study, we wanted to 
investigate possible interactions between demyelination and invasion of human GBM 
xenografts. To allow engraftment of human biopsies we chose the immunodeficient 
NOD/SCID mice, which is not an established model for studying cuprizone-induced 
demyelination. Notably, NOD/SCID mice lack functional B- and T-cells whereas the 
cuprizone model involves autoimmune mechanisms. Thus, we first needed to assess whether 
this strain would exhibit demyelination in response to cuprizone treatment similarly to 
observations from the cuprizone model established in fully immunocompetent C57Bl/6 mice. 
If NOD/SCID mice showed the same response to cuprizone, we then wanted to study the 
biological role of myelin as a substrate for glioblastomas cell migration. From a clinical 
perspective, we also wanted to see if interactions between the tumor cells and the myelin 
sheet could be targeted therapeutically to inhibit glioma cell migration and prolong overall 
survival. The myelin sheaths are fundamental for proper functioning of the CNS, and a 
therapeutic benefit from demyelination therefore seems highly counter-intuitive. However, the 
history of medicine provides numerous examples of extremely potent toxins that have later 
been applied for medical purposes: The Botulinum toxin is now widely used for a variety of 
conditions, including corticollis (87, 88) as well as in cosmetics to improve wrinkles (Botox). 
Arsenic derivates have successfully prolonged survival in patients with acute promyelocytic 
leukaemia (APL) (89).  Moreover, almost every drug is associated with some degree of 
toxicity, and especially cytotoxic agents used in cancer treatment are associated with 
potentially lethal side-effects.  
6.1 The effect of Cuprizone in NOD/SCID mice 
 
In the literature, demyelination in the corpus callosum of mice has been obtained following 
administration of 0. 2 % cuprizone (48, 62, 63, 66-74). The common hallmarks were shown in 
form of lesions in corpus callosum, axonal damage, hydrocephalus, myelin loss, depletion of 
oligodendrocyte progenitor cells (78), and recruitment of microglia into the affected areas (68, 
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76).  Weight loss following cuprizone administration (74) has also been detected. In this 
work, we observed many of these traits, including weight loss, hydrocephalus on MRI, 
depletion of oligodendrocyte precursor cells (NG2) and recruitment of microglia (CD68).  
 
The results from the weight records during administration of cuprizone (fig 5.1.1), showed 
that all mice uniformly lost weight, on average approximately 15 % of the weight at the 
beginning of the experiment. The weight loss was significant and in agreement with findings 
from previous studies (57, 74). However cuprizone mechanisms in association with weight 
loss are not known but findings suggest that (48), the weight loss following cuprizone 
treatment in SCID mice might be caused by cuprizone interference with the gastro-intestinal 
system of the mice.  
The examination of the T2 weighted MRI 8 weeks after cuprizone administration (figure 
5.1.2) revealed the presence of hydrocephalus and increasing dilation of the ventricular 
system. This is also in accordance with previous studies (48)  and cuprizone may have 
contributed to weight loss and the fatigue symptoms observed in the mice. Although the cause 
of hydrocephalus is not fully known, it may be that inflammatory changes associated with 
demyelination compromise the re-absorption of cerebrospinal fluid.  
The myelin loss was observed already from the second week of cuprizone treatment (fig 
5.1.3), with almost complete demyelination towards 8
th
 week. However, we observed some 
variations as the brain harvested at 4 weeks stained stronger for myelin than the brain 
harvested 2 weeks after starting the cuprizone diet. This might reflect a partial remyelination 
as is seen in patients. In addition, earlier studies have demonstrated that partial remyelination 
of corpus callosum takes place at the second week after starting 0.3% cuprizone treatment 
(86), and 5,5 – 6 weeks after starting 0.2 % cuprizone treatment (78), while complete 
demyelination (apoptosis of regenerated cells) occurred from 4, 5 -5 weeks after 0.2 % 
cuprizone administration (78). Although our findings suggest that remyelination occurred 
earlier than what these studies reported, this difference may reflect differences between the 
model systems (NOD/SCID mice vs. C57Bl/6 mice). However, to fully characterise changes 
in the myelin sheath during treatment, this experiment will have to be expanded to include 
more animals at each time point. Due to the time constraints we were only able to do this 
experiment as a pilot. However, combined with the MRI findings and the IHC-results 
showing depletion of oligodendrocyte precursor cells we think this data collectively illustrate 
the effect of cuprizone clearly.  
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Along with myelin staining, we performed IHC against NG2, a marker for oligodendrocyte 
precursors, on brain tumor sections harvested 8 weeks after administering cuprizone. This 
showed almost a complete loss compared to brains harvested from control mice on normal 
diet.  This suggests that the ability to reconstitute the pool of oligodendrocytes is lost after 8 
weeks of treatment with cuprizone causing permanent demyelinated lesions (90). Although 
IHC can not be considered appropriate for quantifying subtle changes in expression levels, the 
difference between the brains from cuprizone treated mice vs. controls were striking. A more 
precise quantification of this difference can also be obtained with quantitative polymerase 
chain reaction (q-RT-PCR).  
 
6.2. The effect of cuprizone on brain tumor progression 
Cell migration along white matter tracts is an important biological mechanism underlying the 
infiltrative growth of gliomas and was already described in early neuropathological studies 
(91). Thus infiltrative growth and glioma cell migration along myelinated nerve fibres makes 
radical surgery impossible, and is the major cause of treatment failure. Whereas anti-
angiogenic therapies have been validated in treating GBMs, specific anti-invasive drugs have 
yet not been designed. Having established that cuprizone induced demyelination in 
NOD/SCID mice we next wanted to investigate how demyelination impacted on glioma cell 
migration and overall growth. In our first experiment, mice were implanted with GBM 
spheroids and were fed cuprizone 1 week after implantation. This experimental design was 
chosen as it mimics the sequence of events in a clinical setting, in which patients are 
diagnosed with a tumor and then undergo therapy. In the second experiment mice received  
0. 2% cuprizone 3 week prior implantation of GBM spheroids. Since demyelination was 
already present before the brains were implanted with tumor tissue, we decided this approach 
would optimal for investigating the role of myelinated fibres as in brain tumor invasion 
 (38, 39).  
 
In both experiments, the cuprizone fed mice lost weight compared to tumor bearing mice. One 
would think that the tumor bearing mice in control group might be affected due to their tumor 
burdon but this was not the case as these mice retained stable weights during the observation 
period. Mice that received cuprizone after the implantations had a slight shorter median 
survival (46 days) than control mice (49 days), but the difference  was not significant (figure 
5.2.1.3; p = 0, 19).  Apart from the tumor burdon affecting both groups, it is possible that side 
  
 
44 
effects of cuprizone such as fatigue and hydrocephalus can have shortened the survival 
somewhat in the cuprizone group. In contrast, mice that received cuprizone prior to tumor 
implantation lived significantly longer than the control mice (figure 5.2.2.2; p = 0,002), and 
all control mice had been sacrificed before any mice in the cuprizone group developed 
symptoms. In studies such as these, the end point is estimated as the day the mice is dead or 
exhibit severe symptoms which lead to the sacrificing of the animal.  The determination of 
end point is an ethical issue and differences between observers in interpreting the results may 
bias the results. In our experiment, it was mostly 2-3 individuals who inspected the animals 
daily. The person who inspected the animals daily belonged to the staff working at the animal 
facility and had not been involved in the experimental design. Thus, we believe the room for 
bias was limited  
 
Although we used MRI to monitor tumor growth we were unable to measure tumor volumes 
since the contrast enhancement was often weak. Apart from that we didn’t observe consistent 
differences between cuprizone treated and control tumors. However, some of the cuprizone 
treated tumors seemed more sharply circumscribed on contrast-enhanced T1 sequences and 
displayed less extensive tumor-associated oedema (figure 5.2.1.2). Thus the MRI findings 
suggested a less invasive growth in some of the cuprizone treated-tumors. In order to assess 
cell proliferation we performed IHC against the proliferation marker Ki-67 (figure 5.2.2.3) 
and found no significant differences in the tumor core between cuprizone treated and control 
tumors. Thus, the differences in survival could not be attributed to a cuprizone-mediated 
inhibition of tumor cell proliferation. In order to explore the possibility that cuprizone 
inhibited myelin-mediated tumor cell migration, we also examined the tumor peripheries. 
However, we had no pan-human specific antibody that reliably recognises all the human 
tumor cells established from this biopsy. Since the brain is largely a post-mitotic organ we 
also stained the tumor periphery for the Ki-67 epitope to detect proliferating tumor cells. 
Notably, cuprizone treated-tumors displayed a significantly less infiltration with proliferating 
tumor cells outside the tumor bulk (p-value = 0. 009). The limitation with using Ki-67 as a 
marker for tumor cells is due to its selectivity for actively cycling cells. Since only a fraction 
of the pool of tumor cells are actively proliferating, this method will not detect all tumor cells. 
However, the fact that the fraction of proliferating tumor cells in the centre of the tumors was 
similar in the two groups, it suggests that this limitation will affect both groups evenly. Thus, 
the immunostaining for Ki-67 suggests that the effect of cuprizone on overall tumor 
progression is mediated through its inhibitory effects on glioma cell migration. 
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Many studies have proved that there is a correlation between the elevated accumulation of 
macrophages (microglia) in cuprizone and CNS demyelination (48, 68, 86). Macrophages are 
present in cells of CNS during normal physiological condition but their amount can multiply 
when the brain get damaged (48, 57) following the cuprizone administration. Microglia cells 
have both neuroprotective, after acute neutoxicity (74) and neurodegenetive function during 
chronic toxic demyelination leading to axon damage  (76). However, since demyelination is 
accompanied by inflammatory changes, it is also possible that this inflammatory environment 
have impacted on tumor cell invasion. Furthermore microglia are recruited both to neoplastic 
and inflammatory lesions in the CNS. We therefore performed immunostaining for the 
microglial marker CD68 on tumor sections from both groups, and examined both the tumor 
core and the tumor periphery (figure 5.2.2.4). Both control and cuprizone-treated tumors 
exhibited infiltration of CD68-positive cells, both in the centre and the periphery. Moreover, 
there seemed to be a stronger recruitment of these cells into the cuprizone treated tumors. This 
consistent with demyelination and inflammatory changes being important factors in attracting 
these cells. Again, IHC data are not suitable for investigating small differences in expression 
levels. Since, CD68-positive cells were also clearly present in control tumors this finding is 
uncertain and will ultimately need confirmation with more quantitative methods. One 
approach could be to dissociate the tumors into cell suspensions and quantitative the fraction 
of CD68-positive cells using flow-cytometry. 
 
The findings in the present study indicate that the therapeutic method commencing cuprizone 
intervention 3 weeks before GBM implantation has a significant effect on gliomas invasion 
and that myelin play a role in facilitating GBM cell invasion. Like previously mentioned, this 
is in agreement with evidence from previous histopathological studies shoving that   invasion 
of gliomas into other regions of the brain parenchyma follows the white matter fiber tracts of 
corpus callosum to the contra lateral hemisphere of the brain (38, 39). This again suggests that 
the myelin can be a target in glioma infiltrative invasion to the brain parenchyma.  
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6.3 Conclusion 
 
 NOD/SCID mice exhibit demyelination in response to cuprizone and display weight 
loss, depletion of oligodendrocyte precursors and hydrocephalus similar to what has 
been reported for other mice strains. This provides a novel model to study how 
impacts on human glioma cell migration demyelination.   
 Onset of cuprizone treatment one week after implanting glioma spheroids did not 
prolong survival in NOD/SCID mice. 
 Cuprizone treatment started 3 weeks before implantation of glioma spheroids 
significantly prolonged survival. Cuprizone did not inhibit cell proliferation, but 
probably inhibited tumor cell invasion. Cuprizone treatment was accompanied by a 
recruitment of CD68-positive cells. 
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7. FUTURE PERSPECTIVES 
This study identifies glioma cell-myelin sheaths interactions as targets for glioma therapy. 
However, the therapeutic potential of Cuprizone itself may be limited due to its destructive 
effect on the myelin. Thus, finding novel compounds that block the attachment of glioma cells 
to the myelin without causing structural injury should be a goal for future work. Since these 
efforts will require animal experiments, we believe the model presented here can provide a 
valuable tool for such studies. However, using this animal model to its full potential will also 
require dedicated MRI imaging sequences that can monitor tumor cell invasion in vivo. Thus 
anti-invasive studies will also require that new imaging tools are developed that are optimised 
and dedicated towards a detailed imaging of tumor invasion.  
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